Serelaxin for the treatment of heart failure

References

• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Failure. 2013;6:606–619.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2015;e1–e323. doi:10.1161/CIR.0000000000000350. [Epub ahead of print].
   Web of Science ®Google Scholar
• Blecker S, Paul M, Taksler G, et al. Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol. 2013;61:1259–1267.
   PubMed Web of Science ®Google Scholar
• Chen J, Normand SL, Wang Y, et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011;306:1669–1678.
   PubMed Web of Science ®Google Scholar
• Adams KF Jr., Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216.
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154:260–266.
   PubMed Web of Science ®Google Scholar
• Chen J, Dharmarajan K, Wang Y, et al. National trends in heart failure hospital stay rates, 2001 to 2009. J Am Coll Cardiol. 2013;61:1078–1088.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Committee ASA. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4 Suppl 7:S21–S30.
   Google Scholar
• Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389–393.
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VI. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–e239.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64.
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547.
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Failure. 2013;1:103–111.
   PubMed Web of Science ®Google Scholar
• Matsue Y, Kagiyama N, Yoshida K, et al. Carperitide is associated with increased in-hospital mortality in acute heart failure: a propensity score-matched analysis. J Card Fail. 2015;21:859–864.
   PubMed Web of Science ®Google Scholar
• Anker SD, Ponikowski P, Mitrovic V, et al. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015;36:715–723.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.
   PubMed Web of Science ®Google Scholar
• Massie BM, O’Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:1419–1428.
   PubMed Web of Science ®Google Scholar
• Chan WY, Frampton CM, Crozier IG, et al. Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy). JACC Heart Failure. 2013;1:433–441.
   PubMed Web of Science ®Google Scholar
• Felker GM, Mentz RJ, Adams KF, et al. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials. Circ Heart Failure. 2015;8:997–1005.
   PubMed Web of Science ®Google Scholar
• Hisaw FL. Experimental relaxation of the pubic ligament of the guinea pig. Exp Biol Med. 1926;23:661–663.
   Google Scholar
• Bullesbach EE, Schwabe C. Total synthesis of human relaxin and human relaxin derivatives by solid-phase peptide synthesis and site-directed chain combination. J Biol Chem. 1991;266:10754–10761.
   PubMed Web of Science ®Google Scholar
• Sherwood OD. Relaxin’s physiological roles and other diverse actions. Endocr Rev. 2004;25:205–234.
   PubMed Web of Science ®Google Scholar
• Hossain MA, Rosengren KJ, Samuel CS, et al. The minimal active structure of human relaxin-2. J Biol Chem. 2011;286:37555–37565.
   PubMed Web of Science ®Google Scholar
• Schwabe C, McDonald JK. Relaxin: a disulfide homolog of insulin. Science. 1977;197:914–915.
   PubMed Web of Science ®Google Scholar
• Lu C, Lam HN, Menon RK. New members of the insulin family: regulators of metabolism, growth and now … reproduction. Pediatr Res. 2005;57:70R–3R.
   PubMed Web of Science ®Google Scholar
• Bani D. Relaxin: a pleiotropic hormone. Gen Pharmacol. 1997;28:13–22.
   PubMedGoogle Scholar
• Winslow JW, Shih A, Bourell JH, et al. Human seminal relaxin is a product of the same gene as human luteal relaxin. Endocrinology. 1992;130:2660–2668.
   PubMed Web of Science ®Google Scholar
• Garibay-Tupas JL, Csiszar K, Fox M, et al. Analysis of the 5ʹ-upstream regions of the human relaxin H1 and H2 genes and their chromosomal localization on chromosome 9p24.1 by radiation hybrid and breakpoint mapping. J Mol Endocrinol. 1999;23:355–365.
   PubMed Web of Science ®Google Scholar
• Hsu SY, Nakabayashi K, Nishi S, et al. Activation of orphan receptors by the hormone relaxin. Science. 2002;295:671–674.
   PubMed Web of Science ®Google Scholar
• Bathgate RA, Samuel CS, Burazin TC, et al. Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. Novel members of the relaxin peptide family. J Biol Chem. 2002;277:1148–1157.
   PubMed Web of Science ®Google Scholar
• Sutton SW, Bonaventure P, Kuei C, et al. G-protein-coupled receptor (GPCR)-142 does not contribute to relaxin-3 binding in the mouse brain: further support that relaxin-3 is the physiological ligand for GPCR135. Neuroendocrinology. 2005;82:139–150.
   PubMed Web of Science ®Google Scholar
• Weiss M, Nagelschmidt M, Struck H. Relaxin and collagen metabolism. Horm Metab Res. 1979;11:408–410.
   PubMed Web of Science ®Google Scholar
• Samuel CS, Coghlan JP, Bateman JF. Effects of relaxin, pregnancy and parturition on collagen metabolism in the rat pubic symphysis. J Endocrinol. 1998;159:117–125.
   PubMed Web of Science ®Google Scholar
• Lenhart JA, Ryan PL, Ohleth KM, et al. Relaxin increases secretion of tissue inhibitor of matrix metalloproteinase-1 and -2 during uterine and cervical growth and remodeling in the pig. Endocrinology. 2002;143:91–98.
   PubMed Web of Science ®Google Scholar
• Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem. 1990;265:10681–10685.
   PubMed Web of Science ®Google Scholar
• Unemori EN, Beck LS, Lee WP, et al. Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J Invest Dermatol. 1993;101:280–285.
   PubMed Web of Science ®Google Scholar
• Bennett RG, Heimann DG, Tuma DJ. Relaxin reduces fibrosis in models of progressive and established hepatic fibrosis. Ann N Y Acad Sci. 2009;1160:348–349.
   PubMed Web of Science ®Google Scholar
• Bennett RG, Heimann DG, Singh S, et al. Relaxin decreases the severity of established hepatic fibrosis in mice. Liver Int. 2014;34:416–426.
   PubMed Web of Science ®Google Scholar
• Garber SL, Mirochnik Y, Brecklin CS, et al. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 2001;59:876–882.
   PubMed Web of Science ®Google Scholar
• Tang ML, Samuel CS, Royce SG. Role of relaxin in regulation of fibrosis in the lung. Ann N Y Acad Sci. 2009;1160:342–347.
   PubMed Web of Science ®Google Scholar
• Du X-J, Bathgate RA, Samuel CS, et al. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Reviews Cardiol. 2010;7:48–58.
   PubMed Web of Science ®Google Scholar
• Samuel CS, Hewitson TD, Unemori EN, et al. Drugs of the future: the hormone relaxin. Cell Mol Life Sci. 2007;64:1539–1557.
   PubMed Web of Science ®Google Scholar
• Samuel CS, Zhao C, Yang Q, et al. The relaxin gene knockout mouse: a model of progressive scleroderma. J Invest Dermatol. 2005;125:692–699.
   PubMed Web of Science ®Google Scholar
• Hampel U, Klonisch T, Makrantonaki E, et al. Relaxin 2 is functional at the ocular surface and promotes corneal wound healing. Invest Ophthalmol Vis Sci. 2012;53:7780–7790.
   PubMed Web of Science ®Google Scholar
• Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology. 2004;145:4125–4133.
   PubMed Web of Science ®Google Scholar
• Sassoli C, Chellini F, Pini A, et al. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-beta/Smad3 signaling. Plos One. 2013;8:e63896.
   PubMed Web of Science ®Google Scholar
• Mookerjee I, Hewitson TD, Halls ML, et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 2009;23:1219–1229.
   PubMed Web of Science ®Google Scholar
• Bani D, Nistri S, Formigli L, et al. Prominent role of relaxin in improving postinfarction heart remodeling. Ann N Y Acad Sci. 2009;1160:269–277.
   PubMed Web of Science ®Google Scholar
• Perna A-M, Masini E, Nistri S, et al. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J. 2005;19:1525–1527.
   PubMed Web of Science ®Google Scholar
• Kakouris H, Eddie LW, Summers RJ. Cardiac effects of relaxin in rats. Lancet. 1992;339:1076–1078.
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Alexiou K, Kinkel H-T, et al. The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling. J Card Fail. 2011;17:158–166.
   PubMed Web of Science ®Google Scholar
• Unemori EN, Erikson ME, Rocco SE, et al. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum Reproduction. 1999;14:800–806.
   PubMed Web of Science ®Google Scholar
• Unemori EN, Lewis M, Constant J, et al. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen. 2000;8:361–370.
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Richter C, Bartsch C, et al. The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 2001;15:2187–2195.
   PubMed Web of Science ®Google Scholar
• Kruger S, Graf J, Merx MW, et al. Relaxin kinetics during dynamic exercise in patients with chronic heart failure. Eur J Intern Med. 2004;15:54–56.
   PubMedGoogle Scholar
• Conrad KP, Debrah DO, Novak J, et al. Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. Endocrinology. 2004;145:3289–3296.
   PubMed Web of Science ®Google Scholar
• Fisher C, MacLean M, Morecroft I, et al. Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation. 2002;106:292–295.
   PubMed Web of Science ®Google Scholar
• Bani D, Failli P, Bello MG, et al. Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture. Hypertension. 1998;31:1240–1247.
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Bartsch C, Richter C, et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res. 2003;92:32–40.
   PubMed Web of Science ®Google Scholar
• Debrah DO, Conrad KP, Novak J, et al. Recombinant human relaxin (rhRLX) modifies systemic arterial properties in conscious rats irrespective of gender, but in a biphasic fashion. Ann N Y Acad Sci. 2005;1041:155–162.
   PubMed Web of Science ®Google Scholar
• Debrah DO, Conrad KP, Jeyabalan A, et al. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension. 2005;46:745–750.
   PubMed Web of Science ®Google Scholar
• Danielson LA, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest. 1999;103:525–533.
   PubMed Web of Science ®Google Scholar
• Seibold JR, Clements PJ, Furst DE, et al. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. J Rheumatol. 1998;25:302–307.
   PubMed Web of Science ®Google Scholar
• Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Intern Med. 2000;132:871–879.
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail. 2009;15:182–190.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429–1439.
   PubMed Web of Science ®Google Scholar
• Reasanz: Briefing Document. 2014. [Accessed 2016 Feb 2]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM390444.pdf
   Google Scholar
• Dahlke M, Ng D, Yamaguchi M, et al. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations. J Clin Pharmacol. 2015;55:415–422.
   PubMed Web of Science ®Google Scholar
• Dahlke M, Halabi A, Canadi J, et al. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study. J Clin Pharmacol. 2015;55:415–422.
   Web of Science ®Google Scholar
• Kobalava Z, Villevalde S, Kotovskaya Y, et al. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study. Br J Clin Pharmacol. 2015;79:937–945.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29–39.
   PubMed Web of Science ®Google Scholar
• Bennett RG, Heimann DG, Hamel FG. Degradation of relaxin family peptides by insulin-degrading enzyme. Ann N Y Acad Sci. 2009;1160:38–41.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Mitrovic V, Ruda M, et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J. 2014;35:431–441.
   PubMed Web of Science ®Google Scholar
• Metra M, Ponikowski P, Cotter G, et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J. 2013;34:3128–3136.
   PubMed Web of Science ®Google Scholar
• Filippatos G, Teerlink JR, Farmakis D, et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J. 2014;35:1041–1050.
   PubMed Web of Science ®Google Scholar
• Felker GM, Teerlink JR, Butler J, et al. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. J Am Coll Cardiol. 2014;64:1591–1598.
   PubMed Web of Science ®Google Scholar
• Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61:196–206.
   PubMed Web of Science ®Google Scholar
• Wang TS, Hellkamp AS, Patel CB, et al. Representativeness of RELAX-AHF clinical trial population in acute heart failure. Circ Cardiovasc Quality Outcomes. 2014;7:259–268.
   PubMed Web of Science ®Google Scholar
• Ander DS, Aisiku IP, Ratcliff JJ, et al. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful?. Congest Heart Failure. 2004;10:188–191.
   PubMedGoogle Scholar